Cabaletta Bio
176 employees
Biotech/Pharma
Public · $88.3M
Open positions (7)
Company details
Team Size176
IndustryBiotech/Pharma
Funding
Total raised
$88.3M
Last stage
Public
Investors
Deerfield Management
Total raised
$88.3M
Last stage
Public
Investors
Aimee Payne
MD, PhD; Penn physician-scientist and professor of Dermatology. Lead physician in the Autoimmune Blistering Clinic at Penn. Serves as co-chair of Cabaletta's Scientific Advisory Board.
Michael Milone
MD, PhD; Penn physician-scientist and co-inventor of Kymriah, the first FDA-approved CAR T cell therapy. Serves as co-chair of Cabaletta's Scientific Advisory Board.
Steven Nichtberger
MD; has served as CEO, President, and Chairman of Cabaletta Bio since its founding in 2017. Also a senior fellow and professor of practice at the Wharton School of the University of Pennsylvania. Previously founding CEO of Tengion and held roles at Merck.
LinkedInNo applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.